The Risk Of Seizure-Related Hospitalization Among Older Adults On Levetiracetam Monotherapy: A Retrospective Comparative Cohort Study

References

• Acharya JN, Acharya VJ. Epilepsy in the elderly: special considerations and challenges. Ann Indian Acad Neurol. 2014;17(Suppl 1):S18–S26. doi:10.4103/0972-2327.12864524791083
   PubMed Web of Science ®Google Scholar
• Picot MC, Baldy-Moulinier M, Daures JP, Dujols P, Crespel A. The prevalence of epilepsy and pharmacoresistant epilepsy in adults: a population-based study in a Western European country. Epilepsia. 2008;49(7):1230–1238. doi:10.1111/j.1528-1167.2008.01926.x18363709
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Elder AT, Kwan P. Epilepsy in later life. Lancet Neurol. 2009;8(11):1019–1030. doi:10.1016/S1474-4422(09)70240-619800848
   PubMed Web of Science ®Google Scholar
• Liu S, Yu W, Lü Y. The causes of new-onset epilepsy and seizures in the elderly. Neuropsychiatr Dis Treat. 2016;12:1425–1434. doi:10.2147/NDT.S10790527382285
   PubMed Web of Science ®Google Scholar
• Johnston A, Smith PEM. Epilepsy in the elderly. Expert Rev Neurother. 2010;10(12):1899–1910. doi:10.1586/ern.10.17021384700
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Kwan P. Epilepsy in elderly people. BMJ. 2005;331(7528):1317–1322. doi:10.1136/bmj.331.7510.18316322020
   PubMed Web of Science ®Google Scholar
• Murray CJ, Lopez AD; World Health Organization. Global Comparative Assessments in the Health Sector: Disease Burden, Expenditures and Intervention Packages. Geneva, (Switzerland): World Health Organization; 1994.
   Google Scholar
• Ngugi AK, Bottomley C, Kleinschmidt I, Sander JW, Newton CR. Estimation of the burden of active and life-time epilepsy: a meta-analytic approach. Epilepsia. 2010;51(5):883–890. doi:10.1111/j.1528-1167.2009.02481.x20067507
   PubMed Web of Science ®Google Scholar
• Chen Z, Liew D, Kwan P. Excess mortality and hospitalized morbidity in newly treated epilepsy patients. Neurology. 2016;87(7):718–725. doi:10.1212/WNL.000000000000298427421539
   PubMed Web of Science ®Google Scholar
• Bautista RE, Glen ET, Wludyka PS, Shetty NK. Factors associated with utilization of healthcare resources among epilepsy patients. Epilepsy Res. 2008;79(2–3):120–129. doi:10.1016/j.eplepsyres.2008.01.00318339521
   PubMed Web of Science ®Google Scholar
• Ip Q, Malone DC, Chong J, Harris RB, Labiner DM. Economic impact of epilepsy and the cost of nonadherence to antiepileptic drugs in older medicare beneficiaries. Epilepsy Behav. 2018;80:208–214. doi:10.1016/j.yebeh.2018.01.00929414554
   PubMed Web of Science ®Google Scholar
• Brodie MJ. Antiepileptic drug therapy the story so far. Seizure. 2010;19(10):650–655. doi:10.1016/j.seizure.2010.10.02721075011
   PubMed Web of Science ®Google Scholar
• Kwan P, Brodie MJ. Phenobarbital for the treatment of epilepsy in the 21st century: a critical review. Epilepsia. 2004;45(9):1141–1149. doi:10.1111/epi.2004.45.issue-915329080
   PubMed Web of Science ®Google Scholar
• Kaniwa N, Saito Y. The risk of cutaneous adverse reactions among patients with the HLA-A* 31:01 allele who are given carbamazepine, oxcarbazepine or eslicarbazepine: a perspective review. Ther Adv Drug Saf. 2013;4(6):246–253. doi:10.1177/204209861349979125114785
   PubMedGoogle Scholar
• Lee SK. Old versus new: why do we need new antiepileptic drugs? J Epilepsy Res. 2014;4(2):39–44. doi:10.14581/jer.1401025625087
   PubMedGoogle Scholar
• French JA, Gazzola DM. New generation antiepileptic drugs: what do they offer in terms of improved tolerability and safety? Ther Adv Drug Saf. 2011;2(4):141–158. doi:10.1177/204209861141112725083209
   PubMedGoogle Scholar
• Nevitt SJ, Sudell M, Weston J, Smith CT, Marson AG. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data. Cochrane Database Syst Rev. 2017;6:CD011412.28661008
   PubMed Web of Science ®Google Scholar
• Glauser T, Ben-Menachem E, Bourgeois B, et al. Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia. 2013;54(3):551–563. doi:10.1111/epi.1207423350722
   PubMed Web of Science ®Google Scholar
• Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005–2009. Epilepsia. 2010;51(4):676–685. doi:10.1111/j.1528-1167.2010.02522.x20196795
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Perucca E, Ryvlin P, Ben-Menachem E, Meencke HJ. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology. 2007;68(6):402–408. doi:10.1212/01.wnl.0000252941.50833.4a17283312
   PubMed Web of Science ®Google Scholar
• Consoli D, Bosco D, Postorino P, et al. Levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project). Cerebrovasc Dis. 2012;34(4):282–289. doi:10.1159/00034266923128439
   PubMed Web of Science ®Google Scholar
• Hakami T, O’Brien TJ, Petty SJ, et al. Monotherapy with levetiracetam versus older AEDs: a randomized comparative trial of effects on bone health. Calcif Tissue Int. 2016;98(6):556–565. doi:10.1007/s00223-016-0109-726842957
   PubMed Web of Science ®Google Scholar
• Almalag HM, Alzahrani H, Al-Hussain F, et al. The impact of old versus new antiepileptic drugs on costs and patient reported outcomes among older adults. Geriatr Nurs. 2018;39(6):669–675. doi:10.1016/j.gerinurse.2017.12.01229859697
   PubMed Web of Science ®Google Scholar
• Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1000–1015. doi:10.1016/S0140-6736(07)60460-717382827
   PubMed Web of Science ®Google Scholar
• Marson AG, Al-Kharusi AM, Alwaidh M, et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial. Lancet. 2007;369(9566):1016–1026. doi:10.1016/S0140-6736(07)60461-917382828
   PubMed Web of Science ®Google Scholar
• Brodie MJ, Overstall PW, Giorgi L. Multicentre, double-blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK lamotrigine elderly study group. Epilepsy Res. 1999;37(1):81–87. doi:10.1016/S0920-1211(99)00039-X10515178
   PubMed Web of Science ®Google Scholar
• Saetre E, Perucca E, Isojarvi J, Gjerstad L. An international multicenter randomized double-blind controlled trial of lamotrigine and sustained-release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia. 2007;48(7):1292–1302. doi:10.1111/j.1528-1167.2007.01128.x17561956
   PubMed Web of Science ®Google Scholar
• Motamedi M, Ghini MR, Etemadi P, Ramim T. Levetiracetam and lamotrigine in old aged onset of epilepsy: a randomized double-blind clinical trial. Tehran Univ Med J. 2013;71(9):568–576.
   Google Scholar
• Rowan AJ, Ramsay RE, Collins JF, et al. New onset geriatric epilepsy: a randomized study of gabapentin, lamotrigine, and carbamazepine. Neurology. 2005;64(11):1868–1873. doi:10.1212/01.WNL.0000167384.68207.3E15955935
   PubMed Web of Science ®Google Scholar
• Werhahn KJ, Trinka E, Dobesberger J, et al. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia. 2015;56(3):450–459. doi:10.1111/epi.1292625684224
   PubMed Web of Science ®Google Scholar
• Arif H, Buchsbaum R, Pierro J, et al. Comparative effectiveness of 10 antiepileptic drugs in older adults with epilepsy. Arch Neurol. 2010;67(4):408–415. doi:10.1001/archneurol.2010.4920385905
   PubMedGoogle Scholar
• Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-83558716
   PubMedGoogle Scholar
• Zelko E, Klemenc-Ketis Z, Tusek-Bunc K. Medication adherence in elderly with polypharmacy living at home: a systematic review of existing studies. Mater Sociomed. 2016;28(2):129–132. doi:10.5455/msm.27147920
   PubMedGoogle Scholar
• Vassar M, Holzmann M. The retrospective chart review: important methodological considerations. J Educ Eval Health Prof. 2013;10:12. doi:10.3352/jeehp.2013.10.1224324853
   PubMedGoogle Scholar
• Zafar A, Shahid R, Nazish S, et al. Nonadherence to antiepileptic medications: still a major issue to be addressed in the management of epilepsy. J Neurosci Rural Pract. 2019;10(1):106–112. doi:10.4103/jnrp.jnrp_136_1830765980
   PubMed Web of Science ®Google Scholar
• Pandey A, Suskin N, Patel T, Choudhry N. Lower educational levels may be an important determinant of adherence to evidenced-based therapies in post-MI patients. J Am Coll Cardiol. 2017;69(11 Supplement):1847. doi:10.1016/j.jacc.2016.11.026
   Web of Science ®Google Scholar